The governments of developing countries should give greater assurance to vaccine manufacturers investing in mRNA technology that they will purchase the shots they produce, the head of the Medicines Patent Pool (MPP) said on Tuesday.

“If low- and middle-income countries want regional production, they have to be ready to buy the product. They cannot be off to the side: their part of the deal is providing the demand,” MPP executive director Charles Gore said on the sidelines of a meeting of the mRNA vaccine technology transfer programme in Cape Town...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.